
NYSE:BSX
This summary was created by AI, based on 10 opinions in the last 12 months.
Boston Scientific Corp (BSX) is currently experiencing significant challenges, with analysts noting a series of lower highs and lows since 2025, leading to a breach of key support levels such as the $50 mark. While the company is recognized as a leader in the medical device sector—especially in non-invasive heart instrumentation—its organic growth has diminished, with recent guidance cuts on critical products like the Watchman device impacting market sentiment. Investor confidence is wavering due to rising competition from peers like MDT, ABT, and JNJ, as well as deteriorating technical indicators, such as being below the 200-day moving average. Despite these challenges, some analysts hint at potential long-term growth due to evolving demographic factors and a shift towards less invasive medical solutions, although immediate prospects appear uncertain.
An extraordinarily well-run company. Great organic growth. A leader in the cardiac rhythm management, and have done that principally organically. The new management in 2012 streamlined operations, became very efficient and enhanced margins on the back of that. This is a company that he wants to continue to own.
(A Top Pick Sep 18/18, Up 11%) They make heart pacers and have expanded into joint replacements through acquisitions. It was poorly managed, but has turned around in the past three years. He's trimmed around $42 to be Pfizer. However, all medical stocks face US politicians bashing them during elections. So, load up on health stocks and do well after the vote.